Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Operating Expenses (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Operating Expenses data on record, last reported at $122.9 million in Q4 2025.

  • For Q4 2025, Operating Expenses rose 40.37% year-over-year to $122.9 million; the TTM value through Dec 2025 reached $434.2 million, up 45.07%, while the annual FY2025 figure was $434.2 million, 45.07% up from the prior year.
  • Operating Expenses reached $122.9 million in Q4 2025 per VRDN's latest filing, up from $110.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $122.9 million in Q4 2025 and bottomed at $14.3 million in Q3 2021.
  • Average Operating Expenses over 5 years is $60.4 million, with a median of $57.7 million recorded in 2023.
  • The widest YoY moves for Operating Expenses: up 191.78% in 2021, down 67.68% in 2021.
  • A 5-year view of Operating Expenses shows it stood at $29.3 million in 2021, then soared by 67.85% to $49.2 million in 2022, then skyrocketed by 45.51% to $71.6 million in 2023, then grew by 22.35% to $87.5 million in 2024, then skyrocketed by 40.37% to $122.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $122.9 million in Q4 2025, $110.6 million in Q3 2025, and $106.8 million in Q2 2025.